Nanoportal Biotech to Unveil Next-Gen Coacervate-Based Gene Delivery Platform at AACR 2026

HANGZHOU, China, April 17, 2026 – Nanoportal Biotech, an innovator in drug delivery systems based on mammalian endogenous protein coacervates, today announced it will showcase breakthroughs in its core technology at the American Association for Cancer Research (AACR) Annual Meeting 2026 in San Diego (April 17–22).

Nanoportal will highlight its novel systems built on Liquid-Liquid Phase Separation (LLPS) principles. The presentations will demonstrate the platform’s superior performance in overcoming long-standing bottlenecks in stem cell engineering and immune cell modification.

Poster Presentation Details

"We are proud to present our latest advancements at AACR, a premier global stage for cancer research," said the Founder of Nanoportal Biotech. "For years, modifying stem and immune cells has required a difficult trade-off between efficiency and safety. Our coacervate platform breaks this cycle, achieving high-efficiency delivery with minimal cytotoxicity. These results validate the versatility of LLPS technology and provide a vital foundation for more accessible cell and gene therapies (CGT)."

About Nanoportal Biotech

Incubated by Westlake University, Nanoportal Biotech is a high-growth company specializing in coacervates and Liquid-Liquid Phase Separation (LLPS). The company develops non-viral platforms to solve the core challenges of delivering macromolecules and gene-editing tools into complex tissues.

Leveraging deep interdisciplinary expertise, Nanoportal’s proprietary technology offers high transfection efficiency and excellent biocompatibility—providing a significant competitive advantage over traditional viral vectors, LNPs, or electroporation in "tough-to-transfect" cell types.